Screener
Novavax NVAX EPS (Diluted)
EPS (Diluted) at other companies
Other financials
Where this comes from
Reported directly by Novavax in its filing.
Tagged under the XBRL concept us-gaap:EarningsPerShareDiluted.
The source filing: Novavax’s 10-Q, filed August 6, 2026.
- Filed
- Aug 6, 2026, 7:50 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001000694-26-000018
| Line item | For the Three Months Ended June 30, 2026 | For the Three Months Ended June 30, 2025 | For the Six Months Ended June 30, 2026 | For the Six Months Ended June 30, 2025 |
|---|---|---|---|---|
| Income tax expense | 1,711 | 946 | 2,696 | 2,146 |
| Net income (loss) | $(53,387) | $106,508 | $(62,878) | $625,154 |
| Net income (loss) per share: | ||||
| Basic | $(0.32) | $0.66 | $(0.38) | $3.87 |
| Diluted | $(0.32) | $0.62 | $(0.38) | $3.55 |
| Weighted average number of common shares outstanding: | ||||
| Basic | 164,574 | 162,019 | 163,929 | 161,536 |
| Diluted | 164,574 | 177,215 | 163,929 | 177,410 |
Item 1. Consolidated Financial Statements
FAQ
- What is Novavax's EPS (diluted)?
- Novavax (NVAX) reported EPS (diluted) of -$0.32 in Q2 2026.
- How has Novavax's EPS (diluted) changed year-over-year?
- Novavax's EPS (diluted) decreased by 151.6% year-over-year, from $0.62 to -$0.32.
- What is the long-term trend for Novavax's EPS (diluted)?
- Over 4 years (2021 to 2025), Novavax's EPS (diluted) has grown at a -43.7% compound annual growth rate (CAGR), from -$23.42 to $2.35.
- What does EPS (diluted) mean?
- Net income divided by the weighted-average number of shares outstanding plus all potentially dilutive securities (stock options, convertibles, warrants). The most conservative EPS measure.
Ask your AI about Novavax's eps (diluted).
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude